Research programme: MEK kinase inhibitors - Array BioPharma

Drug Profile

Research programme: MEK kinase inhibitors - Array BioPharma

Alternative Names: AR 00241389; ARRY-241389

Latest Information Update: 13 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; Novartis
  • Class Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 13 Jul 2010 Preclinical development is ongoing in USA
  • 21 Apr 2010 Array BioPharma enters into a worldwide agreement with Novartis for the development of small-molecule MEK inhibitors
  • 20 Aug 2009 Pharmacodynamics data from animal models of arthritis presented at the 238th National Meeting of the American Chemical Society (238th-ACS-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top